Northern Trust Corp lifted its stake in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 36.5% in the second quarter, according to its most recent filing with the SEC. The fund owned 405,374 shares of the company’s stock after acquiring an additional 108,369 shares during the period. Northern Trust Corp owned approximately 0.86% of Karyopharm Therapeutics worth $3,668,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of KPTI. Teachers Advisors LLC lifted its holdings in shares of Karyopharm Therapeutics by 915.0% during the 1st quarter. Teachers Advisors LLC now owns 420,563 shares of the company’s stock worth $5,400,000 after acquiring an additional 379,127 shares during the last quarter. Candriam Luxembourg S.C.A. lifted its stake in Karyopharm Therapeutics by 154.7% in the second quarter. Candriam Luxembourg S.C.A. now owns 438,000 shares of the company’s stock worth $3,964,000 after purchasing an additional 266,000 shares during the last quarter. Vanguard Group Inc. lifted its stake in Karyopharm Therapeutics by 9.8% in the first quarter. Vanguard Group Inc. now owns 1,236,762 shares of the company’s stock worth $15,880,000 after purchasing an additional 110,093 shares during the last quarter. TIAA CREF Investment Management LLC lifted its stake in Karyopharm Therapeutics by 49.6% in the second quarter. TIAA CREF Investment Management LLC now owns 103,437 shares of the company’s stock worth $936,000 after purchasing an additional 34,315 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its stake in Karyopharm Therapeutics by 34.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 116,036 shares of the company’s stock worth $1,051,000 after purchasing an additional 29,522 shares during the last quarter. 59.52% of the stock is owned by institutional investors.

Shares of Karyopharm Therapeutics Inc. (NASDAQ KPTI) opened at $11.33 on Thursday. Karyopharm Therapeutics Inc. has a one year low of $7.48 and a one year high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Thursday, November 2nd. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 76.83%. analysts predict that Karyopharm Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Several analysts have weighed in on the stock. ValuEngine raised shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 24th. Jefferies Group LLC reissued a “buy” rating on shares of Karyopharm Therapeutics in a research note on Friday, October 13th. BidaskClub raised shares of Karyopharm Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 9th. Robert W. Baird reissued a “buy” rating on shares of Karyopharm Therapeutics in a research note on Friday, November 3rd. Finally, HC Wainwright reissued a “buy” rating and issued a $23.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, November 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $17.33.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.watchlistnews.com/karyopharm-therapeutics-inc-kpti-shares-bought-by-northern-trust-corp/1721008.html.

In other Karyopharm Therapeutics news, SVP Christopher Brett Primiano sold 4,958 shares of the business’s stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $11.25, for a total value of $55,777.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Mansoor Raza Mirza sold 2,882 shares of the business’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $11.00, for a total transaction of $31,702.00. Following the completion of the transaction, the director now owns 2,882 shares in the company, valued at approximately $31,702. The disclosure for this sale can be found here. Insiders sold 15,653 shares of company stock worth $174,728 in the last 90 days. Corporate insiders own 14.71% of the company’s stock.

Karyopharm Therapeutics Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Institutional Ownership by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.